Highly active antiretroviral therapy in resource-poor settings: the experience of Medecins Sans Frontieres

Tassie, J M; Szumilin, E; Calmy, A; Goemaere, E

dc.contributor.author	Tassie, J M
dc.contributor.author	Szumilin, E
dc.contributor.author	Calmy, A
dc.contributor.author	Goemaere, E
dc.date.accessioned	2008-10-24T08:21:36Z
dc.date.available	2008-10-24T08:21:36Z
dc.date.issued	2003-09
dc.identifier.citation	Highly active antiretroviral therapy in resource poor settings: the experience of Medecins Sans Frontieres, 2003, 17 (13):1995-7 AIDS	en
dc.identifier.issn	0269-9370
dc.identifier.pmid	12960832
dc.identifier.doi	10.1097/01.aids.0000076325.42412.a1
dc.identifier.uri	http://hdl.handle.net/10144/39594
dc.description	To access this Research Letter, scroll down to page 1995 in the attachment.	en
dc.description.abstract	We describe the short-term results of highly active antiretroviral therapy (HAART) in seven projects in low and middle income countries. A total of 743 adults were included, and clinical, immunological and virological responses were analysed. At 6 months, outcomes were similar to those observed in western countries, and the probability of remaining on treatment was 94%. The challenge now is to extend access to HAART to the millions in urgent need.
dc.language.iso	en	en
dc.rights	Archived with thanks to AIDS (London, England)	en
dc.subject.mesh	HIV	en
dc.subject.mesh	Resource-poor settings	en
dc.title	Highly active antiretroviral therapy in resource-poor settings: the experience of Medecins Sans Frontieres	en
dc.contributor.department	Medecins Sans Fronteres	en
dc.identifier.journal	AIDS (London, England)	en
refterms.dateFOA	2019-03-04T12:07:53Z
html.description.abstract	We describe the short-term results of highly active antiretroviral therapy (HAART) in seven projects in low and middle income countries. A total of 743 adults were included, and clinical, immunological and virological responses were analysed. At 6 months, outcomes were similar to those observed in western countries, and the probability of remaining on treatment was 94%. The challenge now is to extend access to HAART to the millions in urgent need.